In an increasingly complex healthcare landscape, network meta-analysis (NMA) has become a powerful tool for comparing multiple treatments, even when direct head-to-head trials are lacking. By synthesizing direct and indirect evidence, NMA provides a robust framework for assessing treatment effectiveness, safety, and cost-effectiveness, making it an essential component of evidence-based decision-making.

Payers, health technology assessment (HTA) agencies, and pharmaceutical companies rely on NMA to rank interventions, support reimbursement decisions, and strengthen regulatory submissions.

This session will provide an in-depth exploration of NMA methodologies, practical applications, and real-world impact. Attendees will engage with case studies and gain hands-on experience using R packages such as netmeta and multinma, equipping them with practical skills to conduct and interpret NMAs effectively.

Join us to discover how NMA enhances comparative effectiveness research, informs healthcare policies, and drives optimized patient outcomes in an evolving treatment landscape.